Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: Histopathological and immunohistochemical study

Veterinary Journal

Volumn 189, Issue 3, 2011, Pages 318-322

  Kim, J H ^a   Im, K S ^a   Kim, N H ^a   Yhee, J Y ^a   Nho, W G ^b   Sur, J H ^a  

^a Konkuk University   (South Korea)

^b National Institute of Animal Science   (South Korea)

Author keywords

Dog; HER 3; Mammary tumors; Nuclear protein; Prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BENIGN TUMOR; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOG DISEASE; EPITHELIUM CELL; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANIMALS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

CANIS FAMILIARIS;

EID: 80052856587     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.08.012     Document Type: Article

References (34)

1. Almasri N.M., Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research 2005, 7:R598-R604.
2. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Internal Journal of Cancer 2003, 106:758-765.
3. Black M.M., Speer F.D., Opler S.R. Structural representations of tumor-host relationships in mammary carcinoma; biologic and prognostic significance. American Journal of Clinical Pathology 1956, 26:250-265.
4. Burden S., Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997, 18:847-855.
5. Charpin C., Garcia S., Bouvier C., Martini F., Lavaut M.N., Allasia C., Bonnier P., Andrac L. C-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. British Journal of Cancer 1997, 75:1667-1673.
6. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41:154-161.
7. Giltnane J.M., Moeder C.B., Camp R.L., Rimm D.L. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009, 115:2400-2409.
8. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8132-8136.
9. Hampe J.F., Misdorp W. Tumours and dysplasias of the mammary gland. Bulletin of the World Health Organization 1974, 50:111-133.
10. Hellmen E., Bergstrom R., Holmberg L., Spangberg I.B., Hansson K., Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Veterinary Pathology 1993, 30:20-27.
11. Hsu W.L., Huang H.M., Liao J.W., Wong M.L., Chang S.C. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. The Veterinary Journal 2009, 180:116-123.
12. Jackson-Fisher A.J., Bellinger G., Breindel J.L., Tavassoli F.A., Booth C.J., Duong J.K., Stern D.F. ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Research 2008, 10:R96.
13. Kim J.H., Yu C.H., Yhee J.Y., Im K.S., Sur J.H. Lymphocyte infiltration, expression of interleukin (IL)-1, IL-6 and expression of mutated breast cancer susceptibility gene-1 correlate with malignancy of canine mammary tumours. Journal of Comparative Pathology 2010, 142:177-186.
14. Koumakpayi I.H., Diallo J.S., Le Page C., Lessard L., Gleave M., Begin L.R., Mes-Masson A.M., Saad F. Expression and nuclear localization of ErbB3 in prostate cancer. Clinical Cancer Research 2006, 12:2730-2737.
15. Koutras A.K., Kalogeras K.T., Dimopoulos M.A., Wirtz R.M., Dafni U., Briasoulis E., Pectasides D., Gogas H., Christodoulou C., Aravantinos G., Zografos G., Timotheadou E., Papakostas P., Linardou H., Razis E., Economopoulos T., Kalofonos H.P., Fountzilas G. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer 2008, 99:1775-1785.
16. Koutras A.K., Fountzilas G., Kalogeras K.T., Starakis I., Iconomou G., Kalofonos H.P. The upgraded role of HER3 and HER4 receptors in breast cancer. Critical Reviews in Oncology/Hematology 2010, 74:73-78.
17. Lai W.W., Chen F.F., Wu M.H., Chow N.H., Su W.C., Ma M.C., Su P.F., Chen H., Lin M.Y., Tseng Y.L. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. The Annals of Thoracic Surgery 2001, 72:1868-1876.
18. Lee Y., Cho S., Seo J.H., Shin B.K., Kim H.K., Kim I., Kim A. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast. American Journal of Clinical Pathology 2007, 128:1041-1049.
19. Lemoine N.R., Barnes D.M., Hollywood D.P., Hughes C.M., Smith P., Dublin E., Prigent S.A., Gullick W.J., Hurst H.C. Expression of the ERBB3 gene product in breast cancer. British Journal of Cancer 1992, 66:1116-1121.
20. Lo H.W., Xia W., Wei Y., Ali-Seyed M., Huang S.F., Hung M.C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Research 2005, 65:338-348.
21. Misdorp W. Tumors of the mammary gland. Tumors in Domestic Animals 2002, 587. Iowa State Press, Iowa, USA. D.J. Meuten (Ed.).
22. Neagu A., Musca S., Slatineanu S., Pricop M. Assessment of prognostic factors in breast cancer. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi 2005, 109:276-280.
23. Offterdinger M., Schofer C., Weipoltshammer K., Grunt T.W. C-erbB-3: a nuclear protein in mammary epithelial cells. The Journal of Cell Biology 2002, 157:929-939.
24. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal 2000, 19:3159-3167.
25. Poller D.N., Spendlove I., Baker C., Church R., Ellis I.O., Plowman G.D., Mayer R.J. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. The Journal of Pathology 1992, 168:275-280.
26. Reis-Filho J.S., Pinheiro C., Lambros M.B., Milanezi F., Carvalho S., Savage K., Simpson P.T., Jones C., Swift S., Mackay A., Reis R.M., Hornick J.L., Pereira E.M., Baltazar F., Fletcher C.D., Ashworth A., Lakhani S.R., Schmitt F.C. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. The Journal of Pathology 2006, 209:445-453.
27. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. The Oncologist 1998, 3:237-252.
28. Rungsipipat A., Tateyama S., Yamaguchi R., Uchida K., Miyoshi N., Hayashi T. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. The Journal of Veterinary Medical Science 1999, 61:27-32.
29. Simpson B.J., Weatherill J., Miller E.P., Lessells A.M., Langdon S.P., Miller W.R. C-erbB-3 protein expression in ovarian tumours. British Journal of Cancer 1995, 71:758-762.
30. Sithanandam G., Anderson L.M. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Therapy 2008, 15:413-448.
31. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
32. Tashbaeva R.E., Hwang D.N., Song G.S., Choi N.H., Lee J.H., Lyoo Y.S., Lee S.J., Jung D.I., Kim H.Y., Sur J.H. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Veterinary Pathology 2007, 44:600-606.
33. Witton C.J., Reeves J.R., Going J.J., Cooke T.G., Bartlett J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. The Journal of Pathology 2003, 200:290-297.
34. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology 2001, 2:127-137.